Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today confirmed that its offer to acquire all of QIAGEN’s ordinary shares for an increased price of €43.00 per share in cash will expire at 24:00 hours (Frankfurt am Main local time) / 18:00 hours (New York local time) on Monday, August 10, 2020.
On July 16, 2020, Thermo Fisher and QIAGEN announced that they had entered into an amendment to their acquisition agreement following good faith discussions between the parties. The revised offer price of €43.00 per QIAGEN share represents Thermo Fisher’s best and final offer.
QIAGEN’s Supervisory Board and Managing Board reaffirmed their unanimous support for the offer and unanimously recommend that all QIAGEN shareholders accept and tender all of their QIAGEN shares in the offer prior to the end of the acceptance period. Each of the members of the Supervisory Board and Managing Board has tendered all of their QIAGEN shares in the offer.
If the minimum acceptance threshold of 66.67% of QIAGEN’s issued and outstanding ordinary share capital is not satisfied at the end of the acceptance period on August 10, 2020, the offer will automatically terminate and QIAGEN will be required to pay Thermo Fisher USD 95 million in cash. Thermo Fisher will not launch another offer in the event the current offer fails to meet the minimum acceptance threshold.
Advisors
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are serving as financial advisors to Thermo Fisher, and Wachtell, Lipton, Rosen & Katz is serving as legal counsel.
Source: Biospace